Literature DB >> 3811805

Effects of repeated bupivacaine administration on sciatic nerve and surrounding muscle tissue in rats.

J Kyttä, E Heinonen, P H Rosenberg, T Wahlström, J Gripenberg, T Huopaniemi.   

Abstract

The effects of repeated administration of 0.5% bupivacaine or saline into the sciatic notch of rats were studied by light microscopy, electron microscopy and a neurophysiological technique. Very severe myositis, including local necrosis, developed in six of 12 rats treated twice daily with 1 ml bupivacaine for either 3 or 7 days. A 3-h infusion of 1.5 ml 0.5% bupivacaine resulted in minor injury to muscle tissue. A marked degree of disruption and vacuolization of myelin sheaths was evident in nerves exposed to bupivacaine for 3 days. Lymphocyte accumulation was confined to the area surrounding the nervous tissue in 7 of 10 of the preparations from rats treated for 3 days or by a 3-h infusion. No histological changes were detected in nerve and muscle tissue from the opposite extremity exposed to saline. After a recovery period of 3 weeks, no differences in the nerve or muscle histology were seen between samples from bupivacaine- or saline-treated animals. The amplitude of the compound action potential of sciatic nerves was, however, significantly lower after bupivacaine treatment (7 days, 1 ml twice daily). Thus, impaired function may continue despite the lack of histological intraneural injury.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3811805     DOI: 10.1111/j.1399-6576.1986.tb02488.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  15 in total

Review 1.  [Toxicology of local anesthetics. Clinical, therapeutic and pathological mechanisms].

Authors:  W Zink; B M Graf
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

Review 2.  [Selected emergencies in operative dermatology].

Authors:  K-W Schulte; T Horn
Journal:  Hautarzt       Date:  2004-06       Impact factor: 0.751

Review 3.  Upper extremity regional anesthesia: essentials of our current understanding, 2008.

Authors:  Joseph M Neal; J C Gerancher; James R Hebl; Brian M Ilfeld; Colin J L McCartney; Carlo D Franco; Quinn H Hogan
Journal:  Reg Anesth Pain Med       Date:  2009 Mar-Apr       Impact factor: 6.288

4.  [Development of a soft tissue ulcer after long-term peridural infusion].

Authors:  I Balga; H Gerber; C Konrad; J Diebold
Journal:  Anaesthesist       Date:  2009-02       Impact factor: 1.041

5.  Effect of ropivacaine infiltration on muscle regeneration: a morphometric analysis.

Authors:  D Kapoukranidou; E Amaniti; J Kalpidis; K Karakoulas; G Papazisis; M Albani; D Kouvelas
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

Review 6.  Complications of regional anaesthesia Incidence and prevention.

Authors:  K A Faccenda; B T Finucane
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

7.  Bupivacaine crystal deposits after long-term epidural infusion.

Authors:  I Balga; H Gerber; X H Schorno; F Aebersold Keller; H-P Oehen
Journal:  Anaesthesist       Date:  2013-05-15       Impact factor: 1.041

8.  Controlled release of lidocaine from injectable gels and efficacy in rat sciatic nerve block.

Authors:  A Paavola; J Yliruusi; Y Kajimoto; E Kalso; T Wahlström; P Rosenberg
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

9.  Perineural dexmedetomidine added to ropivacaine causes a dose-dependent increase in the duration of thermal antinociception in sciatic nerve block in rat.

Authors:  Chad M Brummett; Amrita K Padda; Francesco S Amodeo; Kathleen B Welch; Ralph Lydic
Journal:  Anesthesiology       Date:  2009-11       Impact factor: 7.892

10.  Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.

Authors:  Chad M Brummett; Mary A Norat; John M Palmisano; Ralph Lydic
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.